Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Fast Company Elizabeth Segran	23andMe And The FDA Reached A Pivotal Genetic Testing Agreement An FDA decision summary allows DNA-testing company 23andMe to market a genome test that screens for Bloom syndrome, a rare disorder that may lead toward the development of cancer.
Chemistry World February 25, 2015 Rebecca Trager	US opens up home DNA screening The US Food and Drug Administration has, for the first time, authorized a genetic test to be sold directly to consumers. The agency plans to ease the regulatory path for similar screening tests.
Fast Company John Paul Titlow	23andMe Wants To Turn Your DNA Data Into Lucrative New Drugs 23andMe's original business model may have been thwarted by the feds, but that isn't stopping the company from trying new ways to generate revenue. Its latest idea could be a lucrative one: invent new drugs.
The Motley Fool May 28, 2010 Brian Orelli	Is It Time to Make Money Investing in Genetic Testing? Easier said than done.
Pharmaceutical Executive September 1, 2010	The Testing of the Tests FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development.
The Motley Fool June 14, 2010 Bruce Bigelow	Genetic Testing Companies in San Diego, Boston, and San Francisco Studying FDA Letters The letters notify the companies that genome-sequencing tests they offer to consumers are medical devices that require the agency's approval.
Chemistry World March 23, 2015 Andrew Turley	23andMe jumps into drug R&D 23andMe plans to create a therapeutics group that will search for new leads using its database as a research platform.
Fast Company Pavithra Mohan	App Used 23andMe's DNA Database To Block People From Sites Based On Race And Gender Personal genetics company 23andMe discovered that a programmer had used its open API to create a screening mechanism for websites -- which could effectively block people by race, sex, and ancestry.
BusinessWeek January 21, 2010 Rich Jaroslovsky	Web DNA Tests Offer Ease and Enlightenment A comparison of the often entertaining services of Navigenics, 23andMe, and deCODEme.
Fast Company David Lumb	Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period.
Fast Company November 2013 Elizabeth Murphy	To Know You Is To Really Know You A deeper look at the makeup of genetic testing firm 23andme's customers and what their DNA reveals.
AskMen.com Jacob Franek	Genetic Testing Every day the prospect of individualized genetic testing is slowly becoming commonplace, and certain questions about genetic testing are apparent: What kinds of tests are available? Where can I get them? How accurate are they? And what are the costs?
The Motley Fool August 17, 2007 Brian Orelli	FDA's Rigor May Boost Sales The FDA is updating labeling of certain blood-thinning drugs, indicating that patients may want to obtain a genetic test prior to taking the medication. This move may lead to increased testing, and hopefully increased prescriptions.
The Motley Fool August 24, 2007 Brian Orelli	Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it.
The Motley Fool July 9, 2008 Brian Lawler	Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests.
The Motley Fool September 24, 2007 Jack Uldrich	Nanotech Is in the Genes The FDA's stamp of approval on a genetic test that will help patients better understand how they will metabolize anti-blood clot medication gives Nanosphere extra allure. Investors should take note.
The Motley Fool August 26, 2009 Brian Orelli	This One's Growing Through the Recession Sales at Myriad Genetics increased 40% in its recently completed second half of its fiscal year, even if that was a slowdown from the 55% increase in the first half.
Managed Care September 2002	Aetna Chief Wants Coverage For Genetic Tests The CEO of the country's largest for-profit HMO has jumped with both feet into the national discussion about genetic testing's place in health care.
Fast Company David Lumb	Apple Is Planning iPhone Apps That Let You Share Your DNA Down the line, these apps could let users share their DNA data just like iPhone users share their locations now, says MIT Technology Review.
Chemistry World June 6, 2007 Simon Hadlington	Large-Scale Gene Scanning for Common Diseases A multi-center genome scanning project that has analyzed half a million genetic markers in thousands of healthy people and people with a range of common diseases has revealed previously unknown genetic variants of the diseases.
Fast Company November 2013 Elizabeth Murphy	Inside 23andMe founder Anne Wojcicki's $99 DNA Revolution If Wojcicki gets it right, 23andMe could help change the health care industry as we know it. "At $99, we are opening the doors of access," she says. "Genetics is part of an entire path for how you're going to live a healthier life."
Managed Care November 2006 Maureen Glabman	Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part.
Managed Care May 2001 Michael D. Dalzell	Powerful Opportunities For Good and Greed Genetic advances could spawn incredible improvements in health care. Given public demand, they also pose what may be unmanageable issues of resource use...
The Motley Fool August 19, 2004 Charly Travers	Myriad's Making Hope Possible This small biotech provides screens that can help catch cancer. Even with solid growth of product revenue, losses could continue to increase as Myriad moves more drugs into clinical development while it transitions into a drug developer.
The Motley Fool August 20, 2011 Luke Timmerman	Seattle Genetics Wins FDA Approval of First Drug FDA gives a quick turnaround on the new treatment for lymphomas.
Managed Care November 2006 Frank Diamond	Some Still Want To Know When There's Nothing to Be Done The use of genetic testing suggests that people will soon be able to know a lot - in some cases, an awful lot.
Fast Company December 1, 2007 Amanda Bower	Are There Holes In My Genes? A new industry promises to gauge your genetic risk of getting diseases like cancer. Its investors, including John Doerr's Kleiner Perkins and Mark Kvamme's Sequoia Capital, have bet millions that consumers will buy it. Here, the author takes a test.
Wired November 17, 2007 Thomas Goetz	23AndMe Will Decode Your DNA for $1,000. Welcome to the Age of Genomics A much-anticipated Silicon Valley startup called 23andMe offers a thorough tour of your genealogy, tracing your DNA back through the eons.
IndustryWeek October 19, 2011	FDA: A Future Innovation Partner? Could the Food and Drug Administration reform itself to help manufacturers create new medical technologies?
The Motley Fool February 18, 2010 Brian Orelli	Still Restless for an Approval The FDA is like a box of chocolates: You never know what you're going to get -- rejection or acceptance.
The Motley Fool November 30, 2010 Brian Orelli	Better Buy: Exact Sciences or Sequenom? A battle of the diagnostic test makers.
Bio-IT World August 13, 2003 John Rhodes	Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert.
The Motley Fool July 12, 2011 Luke Timmerman	Seattle Genetics' New "Empowered Antibody" Looks Clean in FDA Staff Documents FDA reviews Seattle Genetics' Hodgkin's lymphoma drug.
The Motley Fool March 19, 2007 Brian Lawler	Is Dendreon Doomed? A pivotal FDA regulatory meeting approaches for the development-stage pharma. Investors, take note.
The Motley Fool September 28, 2007 Brian Orelli	Side Effects No Match for This Tag Team Seven large drugmakers have come together to try and find genetic variations that cause medications to have serious side effects in some patients, but not in others.
Managed Care April 2005 Michael Levin-Epstein	Time To Decipher Legislation's DNA Health plans have much at stake as Congress moves to lay down the do's and don'ts about use of info gathered via genetic testing.
Chemistry World January 30, 2015 Rebecca Trager	Myriad calls a ceasefire in court battle over cancer gene tests Myriad Genetics has ended its bid to prevent other companies from producing tests for genetic mutations associated with an increased risk of breast and ovarian cancer that it owned patents on.
BusinessWeek September 5, 2005	Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine.
The Motley Fool November 27, 2006 Brian Lawler	Pharmaxis Gets Good News From the FDA Fast-track designation gives this pharmaceutical stock a bump.
Chemistry World October 25, 2007 Arthur Rogers	European Ethical Guidelines Weigh in Against Mail Order Genetic Tests The Council of Europe (CoE) has come out against mail-order and over-the-counter genetic tests in new ethical guidelines that seek to address dilemmas faced by health services without hobbling scientific progress towards 'personalized medicine'.
The Motley Fool February 4, 2010 Brian Orelli	Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct.
Managed Care June 2002	Oncologists: FDA needs to speed up approval of cancer-fighting drugs A Competitive Enterprise Institute survey of cancer specialists found that almost 8 of 10 oncologists think the FDA's approval process has "hurt their ability, at least once in their medical careers, to treat patients with the best possible care."
The Motley Fool November 3, 2009 Brian Orelli	A Little Distracted, Are You, Merck? The FDA rejects its latest application.
The Motley Fool July 14, 2011 Luke Timmerman	Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel An FDA panel of cancer drug experts recommended in a 10-0 vote that the company's drug for Hodgkin's lymphoma should be cleared for sale in the U.S.
The Motley Fool January 4, 2012 Brian Orelli	This Biotech's Obese To-Do List Is Done Arena resubmits lorcaserin for FDA approval.
The Motley Fool August 22, 2011 Brian Orelli	Speedy in Seattle Seattle Genetics gets an early approval of Adcentris.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
Chemistry World February 22, 2011 Amaya Camara-Campos	Repairing faulty genes Israeli scientists have developed compounds that could be better treatments for genetic diseases than current drugs.
The Motley Fool March 3, 2009 Brian Orelli	A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals.
Pharmaceutical Executive December 1, 2013	FDA Pursues Delicate Balancing Act The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.